Fulcrum Therapeutics vs Kura Oncology
FULC and KURA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FULC and KURA compare
Kura Oncology is the larger company, worth 2.3 times as much as Fulcrum Therapeutics ($666M against $286M).
Fulcrum Therapeutics scores higher on the StockData Score (8 against 1 for Kura Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FULC | KURA |
|---|---|---|
| Size and price | ||
| Market cap | $286M | $666M |
| Share price | $3.75 | $7.49 |
| Change, 1 year | −56.6% | −33.2% |
| Change, 5 years | −75.1% | −46.5% |
| Beta (5Y) | 1.36 | 2.30 |
| Employees | 55 | 260 |
| StockData Score | ||
| Total score | 8 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 8.4× |
| P/B | 0.9× (better) | 37.1× |
| FCF yield | −23.1% | −13.4% (better) |
| Profitability | ||
| Operating margin | – | −394% |
| Net margin | – | −369% |
| FCF margin | – | −112% |
| Return on equity | −32.4% (better) | −225% |
| Return on invested capital | −35.0% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.55 (better) |
| Interest coverage | – | −227.1× |
| Current ratio | 31.35 (better) | 3.60 |
| Altman Z-score | 10.37 (better) | −3.56 |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | −1.5% | – |
| Shareholder yield | −1.5% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 112% | 98.0% |
| Held by insiders | 34.7% | 2.7% |
| Insider net buying, 12 months | −$57.5M | $512K (better) |
| Short interest, % of float | 12.9% | 14.6% |
Go deeper
- FULC stock overview
- FULC income statement
- FULC valuation and score
- KURA stock overview
- KURA income statement
- KURA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.